Casebia Counts On Collaboration In Its Climb To Leadership In Gene Therapy
An Interview With CEO Jim Burns
Casebia Therapeutics, a three-year old start-up in the hotly contested gene therapy space, is the product of a remarkably relaxed joint venture between the German multinational giant Bayer and CRISPR Therapeutics, a leader in conducting the first clinical trial involving the CRISPR-Cas9 editing platform.
You may also be interested in...
The last six weeks have seen the acquisition of AskBio, the launch of a dedicated cell and gene therapy unit and a CAR-T pact with Atara. Bayer is taking the space very seriously.
Rising Leader Christopher Jon Stokes of Eli Lilly explains how some early life lessons in the restorative powers of community has guided a distinctive career path marked by engaging widely, understanding intuitively and listening actively, all in the pursuit of forging productive human connections that strive to “meet the moment” for patients.
Nigerian start-up 54gene seeks to be the first private sector enterprise bent on applying Africa’s rich genetic heritage to solve the world’s most intractable diseases – ethically, without boundaries, for all.